Media headlines about Iradimed (NASDAQ:IRMD) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Iradimed earned a news impact score of 0.24 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 47.4377246159722 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Iradimed (NASDAQ:IRMD) traded down $0.12 during trading hours on Friday, hitting $13.30. The stock had a trading volume of 2,898 shares, compared to its average volume of 21,771. Iradimed has a one year low of $7.85 and a one year high of $15.85. The firm has a market cap of $141.70, a price-to-earnings ratio of 266.00 and a beta of 1.45.
Iradimed (NASDAQ:IRMD) last announced its quarterly earnings data on Tuesday, February 6th. The medical equipment provider reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.04. Iradimed had a return on equity of 3.06% and a net margin of 2.17%. The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $6.72 million. During the same quarter last year, the firm earned $0.11 EPS. Iradimed’s revenue for the quarter was up 11.9% compared to the same quarter last year. sell-side analysts anticipate that Iradimed will post 0.25 EPS for the current fiscal year.
IRMD has been the topic of several recent research reports. Roth Capital initiated coverage on Iradimed in a report on Tuesday, October 31st. They set a “buy” rating and a $16.00 price objective on the stock. Credit Suisse Group initiated coverage on Iradimed in a report on Monday, November 27th. They set a “buy” rating and a $19.00 price objective on the stock. Finally, Zacks Investment Research lowered Iradimed from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $17.33.
In other news, Director Monty K. Allen sold 1,898 shares of Iradimed stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $13.95, for a total transaction of $26,477.10. Following the sale, the director now owns 9,062 shares of the company’s stock, valued at approximately $126,414.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 60.10% of the stock is currently owned by company insiders.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.